









Markets
/
Stocks
/
nasdaq-drrx
/

DURECT Corp

DRRX

View Detailed Chart

1.850USD

+0.015+0.80%

Market hours （ET）Quotes delayed by 15 min

57.42MMarket Cap

LossP/E TTM



DURECT Corp

1.850

+0.015+0.80%

Overview Company Financials

Financials

Intraday

30m

Today

+0.80%

5 Days

+226.00%

1 Month

+177.44%

6 Months

+146.56%

Year to Date

+146.63%

1 Year

+21.69%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 2 analysts

HOLD

Current Rating

2.500

Target Price

36.24%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

DURECT Corp

DRRX

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Amgen Inc

AMGN

Gilead Sciences Inc

GILD

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(0)

Neutral(1)

Buy(10)

Indicators

Sell(0)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.315

Buy

RSI(14)

85.329

Overbought

STOCH(KDJ)(9,3,3)

62.805

Neutral

ATR(14)

0.198

High Vlolatility

CCI(14)

106.339

Buy

Williams %R

37.617

Buy

TRIX(12,20)

4.170

Buy

StochRSI(14)

89.966

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

1.610

Buy

MA10

1.091

Buy

MA20

0.840

Buy

MA50

0.694

Buy

MA100

0.710

Buy

MA200

0.833

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

DURECT Corporation is a late-stage biopharmaceutical company. The Company is engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcoholic hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Therapy designation, and metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. Its commercial pharmaceutical product includes POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology. It has also completed Alcohol-Associated Hepatitis (AHFIRM) Phase 2b study.

Ticker SymbolDRRX

CompanyDURECT Corp

CEOMr. James E. Brown

Websitehttps://www.durect.com/